Scarica l'app Stockscreener
22.73
4.42%
-1.035
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Deutsche Bank Raises Price Target on Sarepta Therapeutics to $14 From $12, Keeps Sell Rating - marketscreener.com
Sarepta Pushes Past Gene Therapy Debacle as RNA Therapies Show Early Promise - BioSpace
Urban-gro, DraftKings, Sarepta Therapeutics, Destiny Tech100 and AMD: Why these 5 stocks are on investors' radars today - MSN
Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results Spark Share Price Rebound - Yahoo Finance UK
Sarepta Therapeutics Shares Early siRNA Data in FSHD and DM1 Trials, Highlights Biomarker Knockdown - Yahoo Finance
UGRO, DKNG, SRPT, DXYZ, AMD: 5 Trending Stocks TodayAdvanced Micro Devices (NASDAQ:AMD) - Benzinga
Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results - Insider Monkey
10 Stocks Investors Are Buying Now: Chewy, Braze, Sarepta, and More - Insider Monkey
BofA reiterates Sarepta Therapeutics stock Underperform on early trial data - Investing.com
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Sarepta Stock Surges 30% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Traders Purchase Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT) - MarketBeat
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Wednesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results - MEXC
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Transcript : Sarepta Therapeutics, Inc.Special Call - marketscreener.com
Sarepta Stock Surges 29% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Sarepta (SRPT) Sees Promising Phase 1/2 Results in Neuromuscular Treatment - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpTime to Buy? - MarketBeat
Sarepta (SRPT) Jumps 26.4% as Investors Refocus on Elevidys Momentum and Upcoming Data Catalysts - Moomoo
Sarepta sees early success with RNAi drugs from Arrowhead - BioPharma Dive
Sarepta Therapeutics’ experimental siRNA therapies show promising early results - Yahoo Finance
Which stocks are gapping on Wednesday? - ChartMill
SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases - Stocktwits
Sarepta Therapeutics (SRPT) Surges 25% on Promising Trial Data - GuruFocus
SRPT: SRP-1001 and SRP-1003 show potent gene knockdown and safety, advancing toward phase III trials - TradingView
Sarepta (SRPT) Reveals Mixed Results in siRNA Programs for Neuro - GuruFocus
Sarepta Therapeutics shares rise on early promise for rare disease drugs - statnews.com
Sarepta (SRPT) Stock: Rises on Early siRNA Trial Data for Muscular Dystrophy Programs - CoinCentral
Sarepta posts data for muscular dystrophy drugs (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.
Sarepta stock surges 14% on early siRNA trial data By Investing.com - Investing.com Canada
Sarepta shares early trial data for two rare disease therapies - Investing.com
Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1 - marketscreener.com
Sarepta shares early clinical data from siRNA treatments for rare diseases - StreetInsider
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta plans to seek full FDA approval of 2 Duchenne treatments - Muscular Dystrophy News
Sarepta Therapeutics: A $2B Business Priced Like It’s Broken (NASDAQ:SRPT) - Seeking Alpha
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares - BioPharma Dive
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada
How FDA Review of Sarepta’s ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - Yahoo Finance
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - MSN
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
SRPT stock up as enrollment begins in DMD gene therapy safety study - MSN
Sarepta to request FDA for traditional approvals for Duchenne drugs - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies - Yahoo Finance
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
MDA 2026: ‘Body of evidence for Elevidys continues to grow’ - Muscular Dystrophy News
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Sarepta plans FDA filing for DMD drug approvals by end of April - Investing.com
Sarepta (SRPT) Plans sNDA Submissions for Duchenne Therapies - GuruFocus
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026 - StreetInsider
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - itemonline.com
How Investors Are Reacting To Sarepta Therapeutics (SRPT) Pushing Duchenne Drugs Toward Full FDA Approval - Sahm
KROS: Is the Discount Book Value a Value Trap? - TradingView
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):